HLA-A*2402-Restricted Multipeptide Vaccine S-488410

National Cancer Institute

Source

A cancer vaccine composed of HLA-*2402-restricted epitope peptides derived from three cancer/testis (CT) antigens, with potential antineoplastic activity. Upon subcutaneous administration, HLA-A*2402-restricted multipeptide vaccine S-488410 may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these CT antigens. CT antigens, normally expressed only in germ cells of the testis, are overexpressed in a wide variety of human cancers.